Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Taro Pharmaceutical Industries (NYSE:TARO) Posts Quarterly Earnings Results, Misses Expectations By $0.26 EPS

researchsnappy by researchsnappy
November 28, 2019
in Healthcare Research
0
Taro Pharmaceutical Industries (NYSE:TARO) Posts Quarterly Earnings Results, Misses Expectations By $0.26 EPS
403
SHARES
2.4k
VIEWS
Share on FacebookShare on Twitter

Taro Pharmaceutical Industries logoTaro Pharmaceutical Industries (NYSE:TARO) released its quarterly earnings data on Monday, November 4th. The company reported $1.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.72 by ($0.26), Fidelity Earnings reports. Taro Pharmaceutical Industries had a net margin of 40.43% and a return on equity of 14.13%. The business had revenue of $160.85 million during the quarter, compared to analyst estimates of $168.60 million.

TARO traded up $1.00 during trading on Wednesday, hitting $95.62. The stock had a trading volume of 75,564 shares, compared to its average volume of 66,725. The firm has a market cap of $3.51 billion, a PE ratio of 13.23 and a beta of 0.43. Taro Pharmaceutical Industries has a 12 month low of $72.97 and a 12 month high of $109.42. The company has a 50 day simple moving average of $80.88 and a 200-day simple moving average of $84.03.

Several equities research analysts recently issued reports on TARO shares. ValuEngine raised shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective (up previously from $105.00) on shares of Taro Pharmaceutical Industries in a research note on Tuesday, November 5th. Finally, Zacks Investment Research lowered shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research note on Friday, November 8th.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

See Also: Calculating net profit and net profit margin ratio

Earnings History for Taro Pharmaceutical Industries (NYSE:TARO)



Receive News & Ratings for Taro Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Detecting and quantifying causal associations in large nonlinear time series datasets

Next Post

Here is the 13th Most Popular Stock Among 752 Hedge Funds

Next Post
Here is the 13th Most Popular Stock Among 752 Hedge Funds

Here is the 13th Most Popular Stock Among 752 Hedge Funds

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News
  • Top Company News

Top 10 Market Research Companies in the world

3 Best Market Research Certifications in High Demand

The Latest Market Research Trends Shaping 2024

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2024 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2024 researchsnappy.com